AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Apptly Health Technologies Corp.

$0.08 -$0.03 (-27.09%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0.08
Day Range
$0.08$0.08
Year Range
$0.03$0.38
Market Cap
527.4K
AVG Volume
1.65K
Trailing/Forward PE
-1.53/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (CAD) · TTM
050K100K150K23 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF Revenue (CAD) · TTM by quarter
PeriodRevenue (CAD) · TTM
25 Q4121.75K
25 Q30
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
23 Q40
23 Q30
Net Income (CAD) · TTM
-15M-10M-5M05M23 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF Net Income (CAD) · TTM by quarter
PeriodNet Income (CAD) · TTM
25 Q4-7.2M
25 Q3110.53K
25 Q2-300.64K
25 Q1-693.18K
24 Q4-598.16K
24 Q3-11.85M
24 Q2-12.08M
24 Q1-12.25M
23 Q4-12.49M
23 Q3-4.71M
Operating Income (CAD) · TTM
-6M-4M-2M023 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF Operating Income (CAD) · TTM by quarter
PeriodOperating Income (CAD) · TTM
25 Q4-5.63M
25 Q3-756.43K
25 Q2-585.53K
25 Q1-490.25K
24 Q4-506.32K
24 Q3-470.74K
24 Q2-812.4K
24 Q1-947.77K
23 Q4-1.18M
23 Q3-1.69M
EBITDA (CAD) · TTM
-6M-4M-2M02M23 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF EBITDA (CAD) · TTM by quarter
PeriodEBITDA (CAD) · TTM
25 Q4-5.13M
25 Q3-252.56K
25 Q2-205.94K
25 Q1-609.23K
24 Q4-636.07K
24 Q3-601.25K
24 Q2-817.46K
24 Q1-205.05K
23 Q4288.62K
23 Q3530.3K
Cash Flows (CAD) · TTM
-3M-2M-1M023 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF Cash Flows (CAD) · TTM by quarter
PeriodCash Flows (CAD) · TTM
25 Q4-2.03M
25 Q3-690.73K
25 Q2-685.53K
25 Q1-588.93K
24 Q4-664.84K
24 Q3-838.65K
24 Q2-1.21M
24 Q1-1.48M
23 Q4-1.66M
23 Q3-1.62M
EPS (CAD) · TTM
-0.2-0.100.123 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF EPS (CAD) · TTM by quarter
PeriodEPS (CAD) · TTM
25 Q4-0.07
25 Q30.04
25 Q2-0
25 Q1-0.05
24 Q4-0.01
24 Q3-0.19
24 Q2-0.19
24 Q1-0.19
23 Q4-0.2
23 Q3-0.07
Expenses (CAD) · TTM
-1M01M2M3M4MSG&ACapex23 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF Expenses (CAD) · TTM by quarter
PeriodExpenses (CAD) · TTM
25 Q43.92M
25 Q3684.05K
25 Q2573.83K
25 Q1411.47K
24 Q4366.24K
24 Q3264.01K
24 Q2430.71K
24 Q1521.57K
23 Q4727.14K
23 Q31.25M
Shares Outstanding · TTM
-200K-100K0100K200K23 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q4
ESVNF Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
25 Q40
25 Q30
25 Q20
25 Q10
24 Q40
24 Q3116.46K
24 Q299.69K
24 Q1109.55K
23 Q461.67K
23 Q3-173.16K
PE Ratio
3.363.383.43.423.44med 3.41Jun 26Jun 26Jul 26Jul 26
ESVNF PE Ratio by quarter
PeriodPE Ratio
Jul 263.4
Jul 263.39
Jul 263.42
Jul 263.42
Jun 263.43
Jun 263.41
Jun 263.38
Jun 263.37
Free Cash Flow Yield
-300%-200%-100%0%med -57.52%Nov 24Feb 25Jun 25Sep 25Jan 26Jun 26Sep 26
ESVNF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-29.19%
Sep 26-28.83%
Sep 26-24.95%
Aug 26-20.01%
Aug 26-23.81%
Aug 26-57.65%
Aug 26-57.39%
Jul 26-57.07%
Jul 26-183.61%
Jul 26-184.56%
Jul 26-182.85%
Jul 26-182.46%
Jun 26-182.37%
Jun 26-183.03%
Jun 26-184.98%
Jun 26-185.65%
Apr 26-178.38%
Apr 26-177.76%
Apr 26-244.03%
Mar 26-31.48%
Mar 26-76.91%
Mar 26-69.07%
Mar 26-69.89%
Feb 26-69.49%
Feb 26-69.31%
Feb 26-69.61%
Feb 26-69.33%
Jan 26-69.6%
Jan 26-59.44%
Jan 26-58.52%
Jan 26-58.53%
Jan 26-59.31%
Dec 25-59.55%
Dec 25-59.01%
Dec 25-59.13%
Dec 25-58.94%
Nov 25-58.28%
Nov 25-57.75%
Nov 25-58.08%
Nov 25-57.97%
Oct 25-58.15%
Oct 25-6.57%
Oct 25-6.56%
Oct 25-6.57%
Oct 25-6.59%
Sep 25-6.59%
Sep 25-6.67%
Sep 25-6.64%
Sep 25-6.65%
Aug 25-6.69%
Aug 25-6.65%
Aug 25-6.65%
Aug 25-6.68%
Aug 25-6.67%
Jul 25-8.46%
Jul 25-8.45%
Jul 25-8.47%
Jul 25-8.54%
Jun 25-8.48%
Jun 25-8.44%
Jun 25-8.54%
Jun 25-8.47%
May 25-8.44%
May 25-8.45%
May 25-8.3%
May 25-8.32%
May 25-8.39%
Apr 25-12.1%
Apr 25-13.46%
Apr 25-13.43%
Apr 25-13.09%
Mar 25-13.01%
Mar 25-12.97%
Mar 25-12.96%
Mar 25-9.82%
Feb 25-9.75%
Feb 25-11.09%
Feb 25-11.67%
Feb 25-11.91%
Jan 25-11.72%
Jan 25-12.32%
Jan 25-9.38%
Jan 25-10.52%
Jan 25-105.01%
Dec 24-151.8%
Dec 24-152.22%
Dec 24-148.04%
Dec 24-105.42%
Nov 24-157.76%
Nov 24-248.58%
Nov 24-241.08%
Nov 24-163.62%
Nov 24-271.89%
Oct 24-133.83%
Oct 24-171.51%
Oct 24-84.63%
Oct 24-85.79%
Sep 24-86.17%
Sep 24-85.83%
Sep 24-85.72%
Price to Sales
20406080100med 57.36Aug 26Aug 26Sep 26Sep 26
ESVNF Price to Sales by quarter
PeriodPrice to Sales
Sep 2657.01
Sep 2657.72
Sep 2666.69
Aug 2683.15
Aug 2669.88
Aug 2628.87
Aug 2629
Jul 2629.16
EV/EBITDA
-50510med -1.61Nov 23Jan 24Feb 24Apr 24Jul 24Sep 24Oct 24
ESVNF EV/EBITDA by quarter
PeriodEV/EBITDA
Oct 24-3.96
Oct 24-4.91
Oct 24-1.46
Oct 24-1.55
Sep 24-1.58
Sep 24-1.56
Sep 24-1.55
Sep 24-4.97
Aug 24-4.99
Aug 24-4.98
Aug 24-4.29
Aug 24-3.88
Aug 24-3.83
Jul 24-2.74
Jul 24-2.75
Jun 24-0.98
Jun 24-2.29
May 24-1.93
May 24-2.3
May 24-2.3
Apr 24-1.29
Apr 24-1.17
Apr 24-1.79
Mar 24-1.78
Mar 24-1.99
Mar 24-2.04
Mar 24-1.61
Feb 24-0.89
Feb 24-1.62
Feb 24-1.37
Feb 24-1.57
Feb 24-1.38
Jan 24-4.23
Jan 24-0.64
Jan 24-0.66
Jan 24-0.85
Dec 23-0.92
Dec 23-0.48
Dec 23-0.4
Dec 232.51
Dec 236.93
Nov 23-4.79
Nov 23-4.75
Nov 234.67
Nov 232.13
Price to Book
02468med 0.66Sep 24Jan 25Apr 25Aug 25Nov 25Feb 26Jul 26
ESVNF Price to Book by quarter
PeriodPrice to Book
Jul 260.18
Jul 260.18
Jul 260.18
Jul 260.18
Jun 260.18
Jun 260.18
Jun 260.18
Jun 260.18
Apr 260.21
Apr 260.21
Apr 260.16
Mar 261.21
Mar 260.49
Mar 260.55
Mar 260.54
Feb 260.55
Feb 260.55
Feb 260.55
Feb 260.55
Jan 260.55
Jan 260.65
Jan 260.66
Jan 260.66
Jan 260.65
Dec 250.65
Dec 250.65
Dec 250.65
Dec 250.65
Nov 250.66
Nov 250.67
Nov 250.66
Nov 250.66
Oct 250.66
Oct 255.64
Oct 255.65
Oct 255.64
Oct 255.62
Sep 255.62
Sep 255.55
Sep 255.58
Sep 255.57
Aug 255.54
Aug 255.57
Aug 255.57
Aug 255.55
Aug 255.56
Jul 255
Jul 255
Jul 254.99
Jul 254.95
Jun 254.99
Jun 255.01
Jun 254.95
Jun 254.99
May 255.01
May 255.01
May 255.09
May 255.08
May 255.04
Apr 254.76
Apr 254.28
Apr 254.29
Apr 254.4
Mar 254.43
Mar 254.44
Mar 254.44
Mar 255.86
Feb 255.9
Feb 255.19
Feb 254.93
Feb 254.83
Jan 254.91
Jan 255.4
Jan 257.1
Jan 256.33
Jan 250.63
Dec 240.44
Dec 240.44
Dec 240.45
Dec 240.63
Nov 240.42
Nov 240.27
Nov 240.28
Nov 240.41
Nov 240.24
Oct 240.52
Oct 240.41
Oct 240.82
Oct 240.81
Sep 240.81
Sep 240.81
Sep 240.81
Sep 240.4
Aug 240.4
Aug 240.4
Aug 240.48
Aug 240.53
Aug 240.54
Jul 240.09
Jul 240.09
Apptly Health Technologies Corp.
ESVNF
Stockpicker

Video analysis: ESVNF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ESVNF

Apptly Commences Trading on the OTCQB and Becomes DTC Eligible

newsfilecorp.com · 2 Sep 2026

Apptly Commences Trading on the OTCQB and Becomes DTC Eligible

Vancouver, British Columbia--(Newsfile Corp. - September 2, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (OTCQB: ESVNF) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced that it has been approved to trade on the OTCQB Venture Market ("OTCQB") in the United States under the symbol "ESVNF", effective September 2, 2026. The Company also confirms that its common shares are eligible for electronic clearing and settlement through the Depository Trust Company ("DTC").

UberDoc Health Technologies Appoints Lemonaid Health Co-Founder Paul Johnson to Advisory Board and Changes Name to Apptly Health Technologies Corp.

newsfilecorp.com · 23 Jun 2026

UberDoc Health Technologies Appoints Lemonaid Health Co-Founder Paul Johnson to Advisory Board and Changes Name to Apptly Health Technologies Corp.

Builder of the U.S. direct-to-consumer telehealth category joins the physician-founded, surgeon-led marketplace as it scales nationwide direct-pay access Advisor Appointment Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, is pleased to announce the appointment of Paul Johnson to its advisory board (the "Advisory Board"). Johnson co-founded Lemonaid Health, the first national direct-to-consumer telehealth service in the United States, and led it as Chief Executive Officer through its US$400 million sale to 23andMe in 2021.

UBERDOC Health Technologies Corp. Announces Proposed Corporate Name Change to Apptly Health Technologies Corp.

newsfilecorp.com · 18 Jun 2026

UBERDOC Health Technologies Corp. Announces Proposed Corporate Name Change to Apptly Health Technologies Corp.

Rebrand reflects the Company's evolution into a marketplace for direct-pay specialty care, built on the UberDoc network and a single principle: the appropriate care, at the appropriate price, by the appropriate physician. Boston, Massachusetts--(Newsfile Corp. - June 18, 2026) - UBERDOC Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) (the "Company") is pleased to announce its intention to change its corporate name to Apptly Health Technologies Corp. ("Apptly").

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.